Prognostic Role of Hepatorenal Function Indexes in Patients With Ebstein Anomaly.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
22 12 2020
Historique:
received: 23 07 2020
revised: 05 10 2020
accepted: 13 10 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 12 3 2021
Statut: ppublish

Résumé

Hepatorenal dysfunction is a risk factor for mortality in patients with chronic tricuspid regurgitation due to acquired heart disease. Ebstein anomaly is the most common cause of primary tricuspid regurgitation in adults with congenital heart disease, but the prevalence and prognostic implications of hepatorenal dysfunction are unknown in this population. The purpose of this study was to determine the risk factors and prognostic implications of hepatorenal dysfunction, as measured primarily by the use of model for end-stage liver disease excluding international normalized ratio (MELD-XI score), as well as looking at other associated factors. This was a retrospective study of adults with Ebstein anomaly who received care at Mayo Clinic from 2003 to 2018. Of 692 patients, the median MELD-XI score was 10.2 (interquartile range: 9.4 to 13.3); 53 (8%) died and 3 (0.4%) underwent heart transplant. MELD-XI was an independent predictor of death/transplant (hazard ratio: 1.32; 95% confidence interval: 1.11 to 2.06; p < 0.001). In the subset of patients with serial MELD-XI scores (n = 416), temporal change in MELD-XI score (ΔMELD-XI) was also a predictor of death/transplant. In the subset of patients who underwent tricuspid valve surgery (n = 344), a post-operative improvement in MELD-XI score (ΔMELD-XI) was associated with improved long-term survival. Impaired right atrial (RA) reservoir strain and elevated estimated RA pressure were associated with worse baseline MELD-XI and ΔMELD-XI scores. Hepatorenal dysfunction is a predictor of mortality in Ebstein anomaly, and RA dysfunction and hypertension are hemodynamic biomarkers that can identify patients at risk for deterioration in hepatorenal function and mortality. These data highlight the prognostic importance of noncardiac organ-system dysfunction, and provide complementary clinical risk stratification metrics for management of these patients.

Sections du résumé

BACKGROUND
Hepatorenal dysfunction is a risk factor for mortality in patients with chronic tricuspid regurgitation due to acquired heart disease. Ebstein anomaly is the most common cause of primary tricuspid regurgitation in adults with congenital heart disease, but the prevalence and prognostic implications of hepatorenal dysfunction are unknown in this population.
OBJECTIVES
The purpose of this study was to determine the risk factors and prognostic implications of hepatorenal dysfunction, as measured primarily by the use of model for end-stage liver disease excluding international normalized ratio (MELD-XI score), as well as looking at other associated factors.
METHODS
This was a retrospective study of adults with Ebstein anomaly who received care at Mayo Clinic from 2003 to 2018.
RESULTS
Of 692 patients, the median MELD-XI score was 10.2 (interquartile range: 9.4 to 13.3); 53 (8%) died and 3 (0.4%) underwent heart transplant. MELD-XI was an independent predictor of death/transplant (hazard ratio: 1.32; 95% confidence interval: 1.11 to 2.06; p < 0.001). In the subset of patients with serial MELD-XI scores (n = 416), temporal change in MELD-XI score (ΔMELD-XI) was also a predictor of death/transplant. In the subset of patients who underwent tricuspid valve surgery (n = 344), a post-operative improvement in MELD-XI score (ΔMELD-XI) was associated with improved long-term survival. Impaired right atrial (RA) reservoir strain and elevated estimated RA pressure were associated with worse baseline MELD-XI and ΔMELD-XI scores.
CONCLUSIONS
Hepatorenal dysfunction is a predictor of mortality in Ebstein anomaly, and RA dysfunction and hypertension are hemodynamic biomarkers that can identify patients at risk for deterioration in hepatorenal function and mortality. These data highlight the prognostic importance of noncardiac organ-system dysfunction, and provide complementary clinical risk stratification metrics for management of these patients.

Identifiants

pubmed: 33334426
pii: S0735-1097(20)37629-4
doi: 10.1016/j.jacc.2020.10.035
pmc: PMC7755072
mid: NIHMS1640622
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2968-2976

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL141448
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Disclosures The MACHD Registry is supported by the Al-Bahar Research grant. Dr. Egbe is supported by National Heart, Lung, and Blood Institute grant K23 HL141448. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Références

Eur J Heart Fail. 2009 Feb;11(2):170-7
pubmed: 19168515
Heart. 2013 Apr;99(7):491-6
pubmed: 23406689
J Card Fail. 2008 Dec;14(10):824-30
pubmed: 19041045
Can J Cardiol. 2019 Dec;35(12):1824-1833
pubmed: 31564390
JACC Cardiovasc Imaging. 2019 May;12(5):925-927
pubmed: 30553666
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Am J Cardiol. 2002 Dec 15;90(12):1405-9
pubmed: 12480058
J Am Coll Cardiol. 2013 Jun 4;61(22):2253-2261
pubmed: 23563127
PLoS One. 2019 Nov 19;14(11):e0225403
pubmed: 31743362
J Am Heart Assoc. 2018 Jul 13;7(14):
pubmed: 30006492
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
J Heart Lung Transplant. 2002 Oct;21(10):1101-8
pubmed: 12398875
Methodist Debakey Cardiovasc J. 2019 Apr-Jun;15(2):138-144
pubmed: 31384377
JACC Cardiovasc Imaging. 2019 Apr;12(4):637-651
pubmed: 30947906
ESC Heart Fail. 2020 Oct;7(5):2589-2596
pubmed: 32588556
Circulation. 2019 Apr 16;139(16):e840-e878
pubmed: 30852913
JACC Heart Fail. 2019 Feb;7(2):87-97
pubmed: 30553904
Circulation. 2008 May 6;117(18):2320-8
pubmed: 18443238
Liver Transpl. 2007 Jan;13(1):30-7
pubmed: 17154400
N Engl J Med. 2008 Sep 4;359(10):1018-26
pubmed: 18768945
Clin Transplant. 2018 Jun;32(6):e13257
pubmed: 29660764

Auteurs

Alexander C Egbe (AC)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: egbe.alexander@mayo.edu.

William R Miranda (WR)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Joseph Dearani (J)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Patrick S Kamath (PS)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Heidi M Connolly (HM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH